The Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NewLink Genetics Corporation Investors and Encourages Investors to Contact the Firm
BusinessWire - Thu Jun 23, 1:21PM CDT
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased NewLink Genetics Corporation ("NewLink" or the "Company"
NLNK: 11.24 (+0.59)
DEADLINE ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against NewLink Genetics Corporation and Reminds Investors with Losses to Contact the Firm
BusinessWire - Thu Jun 23, 4:30AM CDT
Lundin Law PC announces a class action lawsuit has been filed against NewLink Genetics Corporation ("NewLink" or the "Company"
NLNK: 11.24 (+0.59)
NEWLINK SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NewLink Genetics Corporation - NLNK
PR Newswire - Fri Jun 10, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
NLNK: 11.24 (+0.59)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in NewLink Genetics Corporation of Class Action Lawsuit and Upcoming Deadline - NLNK
ACCESSWIRE - Fri Jun 10, 5:21PM CDT
NEW YORK, NY / ACCESSWIRE / June 10, 2016 / Pomerantz LLP announces that a class action lawsuit has been filed against NewLink Genetics Corporation ("NewLink" or the "Company"
NLNK: 11.24 (+0.59)
INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Class Action Involving NewLink Genetics Corporation and a Lead Plaintiff Deadline of July 11, 2016 - NLNK
GlobeNewswire - Fri Jun 10, 9:51AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased NewLink Genetics Corporation (NASDAQ:NLNK) securities between September 17, 2013 and May 9, 2016.
NLNK: 11.24 (+0.59)
How These Biotech's Stocks are Performing? - Clovis Oncology, Illumina, NewLink Genetics and Zafgen
PR Newswire - Thu Jun 09, 7:00AM CDT
Some of the biggest opportunities in the equities market are found in tumultuous industries such as Biotechnology. The segment continues to present a number of remarkable trades as well as potentially good investment that are waiting to be discovered. This morning ActiveWallSt.com features these four biotech stocks in its technical alerts service: Clovis Oncology Inc. (NASDAQ: CLVS), Illumina Inc. (NASDAQ: ILMN), NewLink Genetics Corp. (NASDAQ: NLNK), and Zafgen Inc. (NASDAQ: ZFGN). Learn more about these stocks and receive your complimentary trade alerts at:
ZFGN: 6.28 (+0.23), CLVS: 13.93 (+0.65), NLNK: 11.24 (+0.59), ILMN: 146.59 (+5.70)
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in NewLink Genetics Corporation to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit - NLNK
GlobeNewswire - Wed Jun 08, 2:22PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of NewLink Genetics Corporation (Nasdaq:NLNK) ("NewLink" or the "Company"
NLNK: 11.24 (+0.59)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of NewLink Genetics Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2016 - NLNK
GlobeNewswire - Mon Jun 06, 2:18PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
NLNK: 11.24 (+0.59)
Law Offices of Marc S. Henzel Announces Investigation of Companies for Violations of the Federal Securities Laws
PR Newswire - Mon Jun 06, 8:11AM CDT
The Law Offices of Marc S. Henzel (www.henzellaw.com), a firm focusing on shareholder litigation, gives notice to shareholders of investigation into the following securities for violations of the Federal Securities Laws:
TNGO: 8.06 (-1.14), ENDP: 15.84 (+0.39), GGB: 1.86 (+0.16), HCP: 34.11 (+0.06), UNIS: 3.20 (unch), NLNK: 11.24 (+0.59), ABIL: 4.35 (-0.05)
NewLink Genetics Presents Clinical Data for IDO Pathway Inhibitor Indoximod Combinations at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Mon Jun 06, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK), a biopharmaceutical company focused on bringing novel immuno-oncology medicines to patients, yesterday presented data from two studies on two posters highlighting the combination therapeutic potential of indoximod, an indoleamine-(2,3)-dioxygenase (IDO) pathway inhibitor, at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.
NLNK: 11.24 (+0.59)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against NewLink Genetics Corporation (NLNK) and Lead Plaintiff Deadline: July 11, 2016
ACCESSWIRE - Fri Jun 03, 9:51AM CDT
NEW YORK, NY / ACCESSWIRE / June 3, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed on behalf of those who purchased shares of NewLink Genetics Corporation ("NewLink" or the "Company"
NLNK: 11.24 (+0.59)
NewLink Genetics to Present Data on Indoximod at American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Fri Jun 03, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will present two posters highlighting the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting on June 5 in Chicago.
NLNK: 11.24 (+0.59)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of NewLink Genetics Corporation and Advises Investors With Losses to Contact the Firm
BusinessWire - Thu Jun 02, 2:33PM CDT
Lundin Law PC announces it is investigating claims against NewLink Genetics Corporation ("NewLink" or the "Company"
NLNK: 11.24 (+0.59)
NewLink Genetics to Participate in Jefferies Healthcare Conference
GlobeNewswire - Thu Jun 02, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will participate in the Jefferies 2016 Healthcare Conference in New York.
NLNK: 11.24 (+0.59)
NewLink Genetics Corporation Top Infectious Disease Scientist to Present at Special Zika Conference Called by American Society for Microbiology
GlobeNewswire - Wed Jun 01, 6:00AM CDT
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that Thomas P. Monath M.D., Chief Science Officer and Chief Operating Officer for the Infectious Disease Division of NewLink Genetics, will present at a scientific conference focused on the Zika virus hosted by the American Society for Microbiology (ASM) in collaboration with the American Society for Virology (ASV).
NLNK: 11.24 (+0.59)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of NewLink Genetics Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 11, 2016 - NLNK
ACCESSWIRE - Tue May 31, 12:42PM CDT
NEW YORK, NY / ACCESSWIRE / May 31, 2016 / The following statement is being issued by Levi & Korsinsky, LLP:
NLNK: 11.24 (+0.59)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in NewLink Genetics Corporation to Contact the Firm Before Lead Plaintiff Deadline
Marketwired - Sat May 28, 10:11AM CDT
NEW YORK, NY--(Marketwired - May 28, 2016) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in NewLink Genetics Corporation ("NewLink" or the "Company"
NLNK: 11.24 (+0.59)
NEWLINK SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against NewLink Genetics Corporation
BusinessWire - Fri May 27, 9:07PM CDT
Kahn Swick & Foti, LLC ("KSF"
NLNK: 11.24 (+0.59)